It was a pleasure to meet with Dr Wayne Anderson (UNC School of Medicine, Chapel Hill, NC, US) to discuss his recent study evaluating the safety and tolerability of BIOÂ‑11006 in patients with acute respiratory distress syndrome.
‘A Phase II, Placebo‑Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIOÂ‑11006 Inhalation Solution in Patients with Acute Respiratory Distress Syndrome.‘ (ABSTRACT NUMBER: A2668) was presented at ATS 2021 International Conference, 14-19 May, 2021.
Questions
- What is the rationale for targeting the MARCKS protein (myristoylated alanine rich protein kinase C substrate) in respiratory disease? (0:16)
- Could you tell us a little about BIO-11006, its mechanism of action and the conditions for which it is being investigated? (3:24)
Disclosures: Wayne Anderson has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).
